News

Public · Published

Canaccord Genuity maintains Beam Therapeutics at Buy, lowers price target to $78 from $79

Canaccord Genuity kept its Buy rating on Beam Therapeutics but lowered its price target to $78 from $79. The revised target is 1.3% lower and implies 180.7% upside from the November 4 closing price of $27.79. Recent analyst targets ranged from $30 to $80.

Published:

Updated:

What happened

Canaccord Genuity kept its Buy rating on Beam Therapeutics but lowered its price target to $78 from $79. The revised target is 1.3% lower and implies 180.7% upside from the November 4 closing price of $27.79. Recent analyst targets ranged from $30 to $80.

Confirmed

Global impact / market context

The lower target signals a small reduction in Canaccord’s stated valuation, but its Buy rating was unchanged. If investors use analyst targets to guide expectations, this revision could modestly temper optimism; the article gives no company operating update or explanation for the change.

Analyst inference

Recent analyst targets cited in the article span $30 to $80, showing differing views among firms. Canaccord’s $78 target sits near the top of that range, while the $27.79 reference close is the basis for its stated upside calculation.

Confirmed

What to watch

  1. Check whether Canaccord explains the target cut or changes its rating later; the article provides no reason for the revision or any change to its Buy view. Analyst inference
  2. Compare future analyst targets with the cited $30–$80 range to see whether views are converging or diverging; no later recommendations are reported here. Analyst inference
  3. Look for company updates on research progress, spending, or funding, which could affect costs and cash available; none are included in this article. Analyst inference

Evidence

  • Original source link unavailable